BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Guan J, Harto H, Fu S, Yang K, Zhu S, Li L, Wu L, Golubovskaya V. CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth. Cancers (Basel) 2018;10:E323. [PMID: 30208593 DOI: 10.3390/cancers10090323] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Qi KM, Cao J, Cheng H, Chen ML, Xu W, Qiao JL, Fu CL, Pan XY, Zeng LY, Li ZY, Xu KL. [Clinical analysis of disseminated intravascular coagulation in 6 patients with hematological diseases after CAR-T treatment]. Zhonghua Xue Ye Xue Za Zhi 2019;40:422-5. [PMID: 31207709 DOI: 10.3760/cma.j.issn.0253-2727.2019.05.014] [Reference Citation Analysis]
2 Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, Xu X, Wang C, Zhao S, Lv L, Long J, Lin D, Zhao A, Fang B, Jiang J, Tang S, Gao J. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. Front Immunol 2021;12:609421. [PMID: 33767695 DOI: 10.3389/fimmu.2021.609421] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li X, Feng Y, Shang F, Yu Z, Wang T, Zhang J, Song Z, Wang P, Shi B, Wang J. Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma. Front Oncol 2021;11:703087. [PMID: 34513682 DOI: 10.3389/fonc.2021.703087] [Reference Citation Analysis]
4 Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, Wu L. Hypoxia Selectively Impairs CAR-T Cells In Vitro. Cancers (Basel) 2019;11:E602. [PMID: 31052261 DOI: 10.3390/cancers11050602] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
5 Golubovskaya V, Zhou H, Li F, Valentine M, Sun J, Berahovich R, Xu S, Quintanilla M, Ma MC, Sienkiewicz J, Huang Y, Wu L. Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma. Cancers (Basel) 2021;13:981. [PMID: 33652767 DOI: 10.3390/cancers13050981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Thangaraj JL, Ahn SY, Jung SH, Vo MC, Chu TH, Thi Phan MT, Kwon M, Lee KH, Kim M, Song GY, Yang DH, Ahn JS, Kim HJ, Cho D, Lee JJ. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol 2021;18:1652-61. [PMID: 33980993 DOI: 10.1038/s41423-021-00686-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Scand J Immunol 2020;92:e12910. [PMID: 32471019 DOI: 10.1111/sji.12910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Liu J, Xu N, Wang X, Wang Y, Wu Q, Li X, Pan D, Wang L, Xu Y, Yan J, Li X, Yu L, Yang M. Quantitative radio-thin-layer chromatography and positron emission tomography studies for measuring streptavidin transduced chimeric antigen receptor T cells. J Chromatogr B Analyt Technol Biomed Life Sci 2021;1182:122944. [PMID: 34592686 DOI: 10.1016/j.jchromb.2021.122944] [Reference Citation Analysis]
9 Lim FLWI, Ang SO. Emerging CAR landscape for cancer immunotherapy. Biochem Pharmacol 2020;178:114051. [PMID: 32446888 DOI: 10.1016/j.bcp.2020.114051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer 2019;18:154. [PMID: 31684964 DOI: 10.1186/s12943-019-1092-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
11 Sureban SM, Berahovich R, Zhou H, Xu S, Wu L, Ding K, May R, Qu D, Bannerman-Menson E, Golubovskaya V, Houchen CW. DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers. Cancers (Basel) 2019;12:E54. [PMID: 31878090 DOI: 10.3390/cancers12010054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Int J Med Sci 2021;18:1786-97. [PMID: 33746596 DOI: 10.7150/ijms.46811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines 2021;9:1422. [PMID: 34680541 DOI: 10.3390/biomedicines9101422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]